ELTX (Elicio Therapeutics) Retained Earnings: $-245.50 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ELTX Elicio Therapeutics Inc ELTX
28 GF Score
Price $3.08
! 1 Warning Sign
View Full Analysis

What is Elicio Therapeutics Retained Earnings?

Elicio Therapeutics ELTX -2.22% 28 Retained Earnings is $-245.50 Mil as of Mar. 2026. GuruFocus rates ELTX with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Elicio Therapeutics's retained earnings for the quarter that ended in Mar. 2026 was $-245.50 Mil.

Elicio Therapeutics's quarterly retained earnings declined from Sep. 2025 ($-225.95 Mil) to Dec. 2025 ($-233.67 Mil) and declined from Dec. 2025 ($-233.67 Mil) to Mar. 2026 ($-245.50 Mil).

Elicio Therapeutics's annual retained earnings declined from Dec. 2023 ($-142.20 Mil) to Dec. 2024 ($-194.10 Mil) and declined from Dec. 2024 ($-194.10 Mil) to Dec. 2025 ($-233.67 Mil).


Elicio Therapeutics  (NAS:ELTX) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Elicio Therapeutics Retained Earnings Historical Data

* Premium members only.

The historical data trend for Elicio Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elicio Therapeutics Retained Earnings Chart

Elicio Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial -78.80 -107.01 -142.20 -194.10 -233.67

Elicio Therapeutics Quarterly Data
Mar20 Dec20 Mar21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -205.31 -215.87 -225.95 -233.67 -245.50
ELTX
28GF Score
Elicio Therapeutics Inc ELTX
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elicio Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-245.50 Mil mean?
Elicio Therapeutics (ELTX) has a Retained Earnings of $-245.50 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Elicio Therapeutics and its competitors.
Is Elicio Therapeutics' Retained Earnings too high?
Elicio Therapeutics' current Retained Earnings is $-245.50 Mil. Overall, Elicio Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Elicio Therapeutics' Retained Earnings compare to GOSS and GANX?
Elicio Therapeutics' Retained Earnings of $-245.50 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Elicio Therapeutics and its competitors. Elicio Therapeutics's current Retained Earnings is $-245.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elicio Therapeutics stock overvalued right now?
Elicio Therapeutics (ELTX) has a current Retained Earnings of $-245.50 Mil. The current Retained Earnings is $-245.50 Mil. Elicio Therapeutics' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Elicio Therapeutics (ELTX), the current Retained Earnings is $-245.50 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Elicio Therapeutics Business Description

Other Exchanges 9HA:Germany
Address 451 D Street, Suite 501, 5th Floor, Boston, MA, USA, 02210
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
28GF Score

Get the complete analysis for ELTX

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.08
Price